Candriam Luxembourg S.C.A. boosted its stake in Radius Health, Inc. (NASDAQ:RDUS) by 94.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 115,000 shares of the biopharmaceutical company’s stock after buying an additional 56,000 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.27% of Radius Health worth $5,202,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of RDUS. Ameritas Investment Partners Inc. purchased a new stake in Radius Health during the first quarter valued at $105,000. Sei Investments Co. boosted its stake in Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 690 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 46 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Radius Health during the fourth quarter valued at $197,000. Finally, Karp Capital Management Corp purchased a new stake in Radius Health during the first quarter valued at $217,000.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by $0.23. The business had revenue of $0.98 million during the quarter, compared to analyst estimates of $1.96 million. During the same period in the previous year, the firm earned ($1.01) earnings per share.
Several equities research analysts recently weighed in on the stock. Jefferies Group LLC cut their price objective on shares of Radius Health from $40.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, May 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $65.00 price objective on shares of Radius Health in a research report on Friday, April 28th. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a research report on Friday, April 28th. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Radius Health in a research report on Monday, May 15th. Finally, Maxim Group reaffirmed a “sell” rating on shares of Radius Health in a research report on Monday, May 1st. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $52.80.
In related news, major shareholder Growth N. V. Biotech bought 15,000 shares of Radius Health stock in a transaction on Friday, May 12th. The stock was acquired at an average price of $34.00 per share, with a total value of $510,000.00. Following the acquisition, the insider now directly owns 4,873,799 shares of the company’s stock, valued at $165,709,166. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech bought 40,000 shares of Radius Health stock in a transaction on Thursday, May 25th. The shares were bought at an average cost of $36.25 per share, with a total value of $1,450,000.00. Following the acquisition, the insider now directly owns 4,998,799 shares in the company, valued at $181,206,463.75. The disclosure for this purchase can be found here. Insiders have acquired a total of 230,000 shares of company stock valued at $8,015,800 in the last ninety days. Insiders own 15.00% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health, Inc. (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
